{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:09:00Z","timestamp":1786662540162,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To assess whether glycaemic control is associated with prognosis in people with cancer and pre-existing diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this pre-registered systematic review (PROSPERO: CRD42020223956), PubMed and Web of Science were searched on 25th Nov 2021 for studies investigating associations between glycosylated haemoglobin (HbA<jats:sub>1c<\/jats:sub>) and prognosis in people with diabetes and cancer. Summary relative risks (RRs) and 95% Confidence Intervals (CIs) for associations between poorly controlled HbA<jats:sub>1c<\/jats:sub> or per 1-unit HbA<jats:sub>1c<\/jats:sub> increment and cancer outcomes were estimated using a random-effects meta-analysis. We also investigated the impact of potential small-study effects using the trim-and-fill method and potential sources of heterogeneity using subgroup analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifteen eligible observational studies, reporting data on 10,536 patients with cancer and pre-existing diabetes, were included. Random-effects meta-analyses indicated that HbA<jats:sub>1c<\/jats:sub>\u2009\u2265\u20097% (53\u2009mmol\/mol) was associated with increased risks of: all-cause mortality (14 studies; RR: 1.14 [95% CI: 1.03\u20131.27]; <jats:italic>p-value<\/jats:italic>: 0.012), cancer-specific mortality (5; 1.68 [1.13\u20132.49]; <jats:italic>p-value<\/jats:italic>: 0.011) and cancer recurrence (8; 1.68 [1.18\u20132.38; <jats:italic>p-value<\/jats:italic>: 0.004]), with moderate to high heterogeneity. Dose-response meta-analyses indicated that 1-unit increment of HbA<jats:sub>1c<\/jats:sub> (%) was associated with increased risks of all-cause mortality (13 studies; 1.04 [1.01\u20131.08]; <jats:italic>p-value<\/jats:italic>: 0.016) and cancer-specific mortality (4; 1.11 [1.04\u20131.20]; <jats:italic>p-value<\/jats:italic>: 0.003). All RRs were attenuated in trim-and-fill analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggested that glycaemic control might be a modifiable risk factor for mortality and cancer recurrence in people with cancer and pre-existing diabetes. High-quality studies with a larger sample size are warranted to confirm these findings due to heterogeneity and potential small-study effects. In the interim, it makes clinical sense to recommend continued optimal glycaemic control.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10144-y","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T07:02:53Z","timestamp":1665039773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Suping","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh T.","family":"Kadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"10144_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"10144_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3322\/caac.21342","volume":"66","author":"D Sarfati","year":"2016","unstructured":"Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66:337\u201350.","journal-title":"CA Cancer J Clin"},{"key":"10144_CR3","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone A-M, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290\u2013314.","journal-title":"Cancer"},{"key":"10144_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41416-020-0950-3","volume":"123","author":"K Loeppenthin","year":"2020","unstructured":"Loeppenthin K, Dalton SO, Johansen C, Andersen E, Christensen MB, Pappot H, et al. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication. Br J Cancer. 2020;123:1033\u201340.","journal-title":"Br J Cancer"},{"key":"10144_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3322\/caac.20078","volume":"60","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207\u201321.","journal-title":"CA Cancer J Clin"},{"key":"10144_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.numecd.2020.09.023","volume":"31","author":"S Ling","year":"2021","unstructured":"Ling S, Brown K, Miksza JK, Howells LM, Morrison A, Issa E, et al. Risk of cancer incidence and mortality associated with diabetes: a systematic review with trend analysis of 203 cohorts. Nutr Metab Cardiovasc Dis. 2021;31:14\u201322.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10144_CR7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.2337\/dc20-0204","volume":"43","author":"S Ling","year":"2020","unstructured":"Ling S, Brown K, Miksza JK, Howells L, Morrison A, Issa E, et al. Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care. 2020;43:2313\u201322.","journal-title":"Diabetes Care"},{"key":"10144_CR8","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1001\/jama.2008.824","volume":"300","author":"BB Barone","year":"2008","unstructured":"Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754\u201364.","journal-title":"JAMA"},{"key":"10144_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/dmrr.2582","volume":"31","author":"H Cai","year":"2015","unstructured":"Cai H, Xu Z, Xu T, Yu B, Zou Q. Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res Rev. 2015;31:336\u201343.","journal-title":"Diabetes Metab Res Rev"},{"key":"10144_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00592-019-01337-2","volume":"56","author":"J Ma","year":"2019","unstructured":"Ma J, Wang J, Ge L, Long B, Zhang J. The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis. Acta Diabetol. 2019;56:1103\u201311.","journal-title":"Acta Diabetol"},{"key":"10144_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00125-003-1109-5","volume":"46","author":"CK Chang","year":"2003","unstructured":"Chang CK, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia. 2003;46:595\u2013607.","journal-title":"Diabetologia"},{"key":"10144_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.clon.2018.01.003","volume":"30","author":"R Barua","year":"2018","unstructured":"Barua R, Templeton AJ, Seruga B, Ocana A, Amir E, Ethier JL. Hyperglycaemia and survival in solid tumours: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2018;30:215\u201324.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10144_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:1\u201343.","journal-title":"Diabetes Res Clin Pract"},{"key":"10144_CR14","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"The ADVANCE Collaborative Group","year":"2008","unstructured":"The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"10144_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"10144_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"10144_CR17","doi-asserted-by":"publisher","first-page":"d2090","DOI":"10.1136\/bmj.d2090","volume":"343","author":"DG Altman","year":"2011","unstructured":"Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011;343:d2090.","journal-title":"BMJ"},{"key":"10144_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","volume":"17","author":"Y Wei","year":"2017","unstructured":"Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2017;17:786\u2013802.","journal-title":"Stata J"},{"key":"10144_CR19","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc21-S006","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44:S73\u201384.","journal-title":"Diabetes Care"},{"key":"10144_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/oxfordjournals.aje.a008971","volume":"144","author":"G Ch\u00eane","year":"1996","unstructured":"Ch\u00eane G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol. 1996;144:610\u201321.","journal-title":"Am J Epidemiol"},{"key":"10144_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","volume":"135","author":"S Greenland","year":"1992","unstructured":"Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301\u20139.","journal-title":"Am J Epidemiol"},{"key":"10144_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/1536867X0600600103","volume":"6","author":"N Orsini","year":"2006","unstructured":"Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose\u2013response data. Stata J. 2006;6:40\u201357.","journal-title":"Stata J"},{"key":"10144_CR23","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/annonc\/mdv106","volume":"26","author":"S Gourgou-Bourgade","year":"2015","unstructured":"Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (definition for the assessment of time-to-event endpoints in CANcer trials)\u2020. Ann Oncol. 2015;26:873\u20139.","journal-title":"Ann Oncol"},{"key":"10144_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"10144_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"10144_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"10144_CR27","doi-asserted-by":"crossref","unstructured":"Ahn JH, Jung SI, Yim SU, Kim SW, Hwang EC, Kwon DD. Impact of glycemic control and metformin use on the recurrence and progression of non-muscle invasive bladder cancer in patients with diabetes mellitus. J Korean Med Sci. 2016;31:1464\u201371.","DOI":"10.3346\/jkms.2016.31.9.1464"},{"key":"10144_CR28","doi-asserted-by":"crossref","unstructured":"Boursi B, Giantonio BJ, Lewis JD, Haynes K, Mamtani R, Yang YX. Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. Eur J Cancer. 2016;59:90\u20138.","DOI":"10.1016\/j.ejca.2016.02.018"},{"key":"10144_CR29","doi-asserted-by":"crossref","unstructured":"Cheon YK, Koo JK, Lee YS, Lee TY, Shim CS. Elevated hemoglobin A1c levels are associated with worse survival in advanced pancreatic cancer patients with diabetes. Gut Liver. 2014;8:205\u201314.","DOI":"10.5009\/gnl.2014.8.2.205"},{"key":"10144_CR30","doi-asserted-by":"crossref","unstructured":"Huang WL, Huang KH, Huang CY, Pu YS, Chang HC, Chow PM. Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study. BMC Urol. 2020;20:117.","DOI":"10.1186\/s12894-020-00684-5"},{"key":"10144_CR31","doi-asserted-by":"crossref","unstructured":"Hwang EC, Kim YJ, Hwang IS, Hwang JE, Jung SI, Kwon DD, et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol. 2011;18:769\u201376.","DOI":"10.1111\/j.1442-2042.2011.02845.x"},{"key":"10144_CR32","doi-asserted-by":"crossref","unstructured":"Kaneda K, Uenishi T, Takemura S, Shinkawa H, Urata Y, Sakae M, et al. The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol. 2012;105:606\u201311.","DOI":"10.1002\/jso.22137"},{"key":"10144_CR33","doi-asserted-by":"crossref","unstructured":"Kang SG, Hwang EC, Jung SI, Yu HS, Chung HS, Kang TW, et al. Poor preoperative glycemic control is associated with dismal prognosis after radical nephroureterectomy for upper tract urothelial carcinoma: a korean multicenter study. Cancer Res Treat. 2016;48:1293\u2013301.","DOI":"10.4143\/crt.2016.021"},{"key":"10144_CR34","doi-asserted-by":"crossref","unstructured":"Komatsu T, Chen-Yoshikawa TF, Ikeda M, Takahashi K, Nishimura A, Harashima SI, et al. Impact of diabetes mellitus on postoperative outcomes in individuals with non-small-cell lung cancer: A retrospective cohort study. PLoS One. 2020;15:e0241930.","DOI":"10.1371\/journal.pone.0241930"},{"key":"10144_CR35","doi-asserted-by":"crossref","unstructured":"Lee W, Yoon YS, Han HS, Cho JY, Choi Y, Jang JY, et al. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma. J Surg Oncol. 2016;113:203\u20138.","DOI":"10.1002\/jso.24133"},{"key":"10144_CR36","doi-asserted-by":"crossref","unstructured":"Lee SJ, Kim JH, Park SJ, Ock SY, Kwon SK, Choi YS, et al. Optimal glycemic target level for colon cancer patients with diabetes. Diabetes Res Clin Pract. 2017;124:66\u201371.","DOI":"10.1016\/j.diabres.2016.12.009"},{"key":"10144_CR37","doi-asserted-by":"crossref","unstructured":"Li J, Ning NY, Rao QX, Chen R, Wang LJ, Lin ZQ. Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease. BMC Cancer. 2017;17:517.","DOI":"10.1186\/s12885-017-3510-3"},{"key":"10144_CR38","doi-asserted-by":"crossref","unstructured":"Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, et al. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer. 2019;125:2861\u20137.","DOI":"10.1002\/cncr.32141"},{"key":"10144_CR39","doi-asserted-by":"crossref","unstructured":"Okamura A, Watanabe M, Imamura Y, Hayami M, Yamashita K, Kurogochi T, et al. Glycemic status and prognosis of patients with squamous cell carcinoma of the esophagus. World J Surg. 2017;41:2591\u20137.","DOI":"10.1007\/s00268-017-4036-1"},{"key":"10144_CR40","doi-asserted-by":"crossref","unstructured":"Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci. 2008;53:2486\u201394.","DOI":"10.1007\/s10620-008-0264-4"},{"key":"10144_CR41","doi-asserted-by":"crossref","unstructured":"Tai YS, Chen CH, Huang CY, Tai HC, Wang SM, Pu YS. Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev. 2015;31:307\u201314.","DOI":"10.1002\/dmrr.2614"},{"key":"10144_CR42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S0140-6736(06)69703-1","volume":"368","author":"KH Yoon","year":"2006","unstructured":"Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368:1681\u20138.","journal-title":"Lancet"},{"key":"10144_CR43","doi-asserted-by":"publisher","first-page":"e5602","DOI":"10.1097\/MD.0000000000005602","volume":"95","author":"XB Zhao","year":"2016","unstructured":"Zhao XB, Ren GS. Diabetes mellitus and prognosis in women with breast cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e5602.","journal-title":"Medicine (Baltimore)"},{"key":"10144_CR44","doi-asserted-by":"publisher","first-page":"e7981","DOI":"10.1097\/MD.0000000000007981","volume":"96","author":"S Chen","year":"2017","unstructured":"Chen S, Tao M, Zhao L, Zhang X. The association between diabetes\/hyperglycemia and the prognosis of cervical cancer patients: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e7981.","journal-title":"Medicine (Baltimore)"},{"key":"10144_CR45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1097\/DCR.0b013e3182a479f9","volume":"56","author":"KT Mills","year":"2013","unstructured":"Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013;56:1304\u201319.","journal-title":"Dis Colon Rectum"},{"key":"10144_CR46","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/1759-7714.12985","volume":"10","author":"HY Deng","year":"2019","unstructured":"Deng HY, Zheng X, Zha P, Peng L, Huang KL, Qiu XM. Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: a comprehensive systematic review and meta-analysis. Thorac Cancer. 2019;10:571\u20138.","journal-title":"Thorac Cancer"},{"key":"10144_CR47","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1007\/s12035-015-9115-4","volume":"53","author":"H Liu","year":"2016","unstructured":"Liu H, Liu Z, Jiang B, Ding X, Huo L, Wan X, et al. Prognostic significance of hyperglycemia in patients with brain tumors: a meta-analysis. Mol Neurobiol. 2016;53:1654\u201360.","journal-title":"Mol Neurobiol"},{"key":"10144_CR48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12020-020-02376-4","volume":"70","author":"C Lin","year":"2020","unstructured":"Lin C, Cai X, Yang W, Lv F, Nie L, Ji L. Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine. 2020;70:232\u201342.","journal-title":"Endocrine"},{"key":"10144_CR49","doi-asserted-by":"publisher","unstructured":"Lin C, Cai X, Yang W, Lv F, Nie L, Ji L. The body weight alteration and incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Front Endocrinol. 2020;11:541699. https:\/\/doi.org\/10.3389\/fendo.2020.541699.","DOI":"10.3389\/fendo.2020.541699"},{"issue":"Suppl 1","key":"10144_CR50","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/bjc.2015.23","volume":"112","author":"SC Hiom","year":"2015","unstructured":"Hiom SC. Diagnosing cancer earlier: reviewing the evidence for improving cancer survival. Br J Cancer. 2015;112(Suppl 1):S1\u20135.","journal-title":"Br J Cancer"},{"key":"10144_CR51","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.2337\/dc13-0045","volume":"36","author":"IN Colmers","year":"2013","unstructured":"Colmers IN, Majumdar SR, Yasui Y, Bowker SL, Marra CA, Johnson JA. Detection bias and overestimation of bladder cancer risk in type 2 diabetes: a matched cohort study. Diabetes Care. 2013;36:3070\u20135.","journal-title":"Diabetes Care"},{"key":"10144_CR52","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/bjc.2017.127","volume":"116","author":"LTA Mounce","year":"2017","unstructured":"Mounce LTA, Price S, Valderas JM, Hamilton W. Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records. Br J Cancer. 2017;116:1536\u201343.","journal-title":"Br J Cancer"},{"key":"10144_CR53","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10549-015-3323-5","volume":"150","author":"LL Lipscombe","year":"2015","unstructured":"Lipscombe LL, Fischer HD, Austin PC, Fu L, Jaakkimainen RL, Ginsburg O, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Res Treat. 2015;150:613\u201320.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10144_CR54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ejon.2015.03.006","volume":"19","author":"JH Park","year":"2015","unstructured":"Park JH, Kim H-y, Lee H, Yun EK. A retrospective analysis to identify the factors affecting infection in patients undergoing chemotherapy. Eur J Oncol Nurs. 2015;19(6):597\u2013603.","journal-title":"Eur J Oncol Nurs"},{"key":"10144_CR55","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc09-1721","volume":"33","author":"BB Barone","year":"2010","unstructured":"Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010;33:931\u20139.","journal-title":"Diabetes Care"},{"key":"10144_CR56","doi-asserted-by":"crossref","unstructured":"Parnham MJ, Nijkamp FP. Principles of Immunopharmacology. Basel: Birkh\u00e4user Verlag; 2005.","DOI":"10.1007\/3-7643-7408-X"},{"key":"10144_CR57","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","volume":"118","author":"CG Lenneman","year":"2016","unstructured":"Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118:1008\u201320.","journal-title":"Circ Res"},{"key":"10144_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1210\/endrev\/bnz014","volume":"41","author":"IC Lega","year":"2019","unstructured":"Lega IC, Lipscombe LL. Review: diabetes, obesity, and cancer\u2014pathophysiology and clinical implications. Endocr Rev. 2019;41:33\u201352.","journal-title":"Endocr Rev"},{"key":"10144_CR59","volume-title":"One-year and five-year net survival for adults (15\u201399) in England diagnosed with one of 29 common cancers, by age and sex","author":"Office for National Statistics","year":"2019","unstructured":"Office for National Statistics. One-year and five-year net survival for adults (15\u201399) in England diagnosed with one of 29 common cancers, by age and sex. 2019."},{"key":"10144_CR60","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/COC.0000000000000612","volume":"42","author":"LC Pinheiro","year":"2019","unstructured":"Pinheiro LC, Kaur H, Nilo D, Safford MM, DeRosa AP, Kern LM. Determining the impact of a cancer diagnosis on diabetes management: a systematic literature review. Am J Clin Oncol. 2019;42:870\u201383.","journal-title":"Am J Clin Oncol"},{"key":"10144_CR61","doi-asserted-by":"crossref","unstructured":"Giovannucci E. The critical need for guidance in managing glycaemic control in patients with cancer. Diabet Med. 2022;39(1):e14624.","DOI":"10.1111\/dme.14624"},{"key":"10144_CR62","doi-asserted-by":"crossref","unstructured":"Joharatnam-Hogan N, Chambers P, Dhatariya K, Board R; Joint British Diabetes Society for Inpatient Care (JBDS), UK Chemotherapy Board (UKCB). A guideline for the outpatient management of glycaemic control in people with cancer. Diabet Med. 2022;39(1):e14636.","DOI":"10.1111\/dme.14636"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10144-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T08:05:47Z","timestamp":1665043547000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10144-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10144"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10144-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was pre-registered within PROSPERO (No. CRD42020223956). Since this study used only secondary data from publications, no ethical approval or consent to participants is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participants"}},{"value":"Not applicable to seek consent to publish from participants, as this study used only secondary data from publications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The preliminary results of this study were presented at European Diabetes Epidemiology Group meeting (EDEG) 2021. We have no conflict of interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1048"}}